Analysts Set Enanta Pharmaceuticals Inc (ENTA) Price Target at $38.00
Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have received an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $38.00.
ENTA has been the topic of a number of recent analyst reports. BidaskClub upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 11th. ValuEngine upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. Robert W. Baird lifted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, August 8th. Finally, JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target on the stock in a research report on Tuesday, July 11th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENTA. Stonepine Capital Management LLC boosted its position in shares of Enanta Pharmaceuticals by 165.9% during the second quarter. Stonepine Capital Management LLC now owns 492,265 shares of the biotechnology company’s stock valued at $17,712,000 after purchasing an additional 307,166 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Enanta Pharmaceuticals by 129.7% during the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after purchasing an additional 233,265 shares in the last quarter. State Street Corp boosted its position in shares of Enanta Pharmaceuticals by 31.8% during the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after purchasing an additional 180,586 shares in the last quarter. ING Groep NV bought a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $3,274,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $1,731,000. Institutional investors own 66.07% of the company’s stock.
Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded up 0.26% during trading on Wednesday, reaching $42.97. The company’s stock had a trading volume of 142,554 shares. The stock’s market cap is $820.30 million. Enanta Pharmaceuticals has a 52-week low of $21.52 and a 52-week high of $45.14. The stock’s 50 day moving average price is $39.15 and its 200-day moving average price is $33.44.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The firm had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 12.83% and a negative net margin of 112.18%. The business’s quarterly revenue was down 46.3% compared to the same quarter last year. During the same period last year, the company earned ($0.06) EPS. Equities analysts anticipate that Enanta Pharmaceuticals will post $0.90 EPS for the current year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Stock Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.